Hibercell, a new biotech company, is focusing on killing off new but dormant cancer cells before they wake up and cause trouble.
Several of the biggest names in biotech venture capital are funding this company with an initial investment of $60 million dollars. HiberCell intends to develop therapies that target dormant cancer cells. Dormant cancer cells are malignant cancer cells that spread throughout the body even before a tumor is detectable with current machines and blood tests.
Finding and destroying these sleeping cancer cells prevents the cancer from starting, growing, and spreading. In many cases, cancers are detected when they have already progressed to Stage-Stage 4, and it’s too late to save the patient.
HiberCell will target both solid tumors, especially breast, prostate, and blood cancers. It also calls itself the first company exclusively focused on the detection and treatment of dormant tumor cells.